Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

A Study to Understand the Analgesic Properties of Topically Applied Menthol When Used in a Marathon.

27 april 2026 bijgewerkt door: Reckitt Benckiser Healthcare (UK) Limited

A Real-world Evidence Study to Understand the Analgesic Properties of Topically Applied Menthol When Used in a Marathon.

The purpose of the research study is to gather the opinions and/or perceptions relating to the use of topically applied menthol and experience of pain during and after a marathon in adult runners (18+ years) participating in the 2025 Chicago Marathon. The main questions it aims to answer are:

  • Does topically applied menthol reduce pain levels in marathon runners during recovery?
  • How quickly does pain relief occur after topically applied menthol application?
  • What are the sensory attributes (e.g., cooling sensation) associated with topically applied menthol use during and after the race?
  • How do demographic factors (e.g., age, sex, menstrual cycle stage, sleep quality) influence pain experience and topically applied menthol effectiveness?

Researchers will compare pre- and post-application pain scores in the Recovery Application Zone to see if Biofreeze provides measurable pain relief and sensory benefits.

Participants will:

  • Provide documented informed consent prior to participation.
  • Self-select to use Biofreeze products during or after the race.

  • Complete one or both of the following:

    1. Recovery Application Zone Questionnaire (includes pain score before and after Biofreeze application, sensory assessments, demographics).
    2. End of Race Questionnaire (includes retrospective recall of pain relief, product use, sensory experience, and demographic data).

Studie Overzicht

Toestand

Voltooid

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

This is a real-world, observational study evaluating self-selected use of topically applied menthol among runners in the 2025 Chicago Marathon.

Participants independently choose whether to use topically applied menthol products, which products to use, and how frequently to apply them as part of their usual pain-management behaviour.

The study does not assign or administer any intervention. Data are collected from participants who voluntarily used topically applied menthol and chose to complete the questionnaires.

Participants may self-select to use topically applied menthol products during the race or recovery as they normally would. Researchers do not assign or direct product use. Product application occurs independently of study participation.

Studietype

Observationeel

Inschrijving (Werkelijk)

367

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

  • Verenigde Staten
    • Illinois
      • Deerfield, Illinois, Verenigde Staten, 60015
        • Curion Strategic Product Insights

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Volwassen
  • Oudere volwassene

Accepteert gezonde vrijwilligers

Ja

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

This study will recruit runners over 18 years old, participating in the 2025 Chicago Marathon, capable of providing documented informed consent, who are not employees of Sponsor or the vendor collecting data.

Beschrijving

Inclusion Criteria:

  1. Participant has provided documented informed consent.
  2. Participant aged 18 years and above.
  3. Participant is entrant into the Chicago marathon 2025.
  4. Participant has self-selected to use topically applied menthol during the race or during immediate recovery.
  5. Comprehension of and able to read English.

Exclusion Criteria:

1. Employee of Sponsor or Agency/ vendor collecting the data

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

Cohorten en interventies

Groep / Cohort
Interventie / Behandeling
Chicago Marathon Runners who use topically applied menthol
Ander: Observational
Pain-experience observational study conducted during a marathon.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change in Mean Pain Score
Tijdsspanne: Day 1 - immediately at the end of the race, assessed within the Recovery Application Zone Questionnaire.
Pain relief was assessed by change in Numeric Rating Scale (NRS) 0-10 pre and post topical menthol application.
Day 1 - immediately at the end of the race, assessed within the Recovery Application Zone Questionnaire.

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Proportion of participants reporting pain relief within 10 seconds after completed application of topically applied menthol.
Tijdsspanne: Day 1 - immediately at the end of the race, assessed within the Recovery Application Zone Questionnaire.

Characterising the speed of analgesic effect from topically applied menthol in participants recovering from marathon.

Number of subjects whose pain score based on 0-10 NRS rating reduced from pre-application to post-application, whose post-application score was within 10 seconds.
Day 1 - immediately at the end of the race, assessed within the Recovery Application Zone Questionnaire.
Percentage of participants which report pain relief reduction of 2 points or greater on NRS within 10 seconds of topically applied menthol application.
Tijdsspanne: Day 1 - immediately at the end of the race, assessed within the Recovery Application Zone Questionnaire.

Characterising the speed of analgesic effect from topically applied menthol in participants recovering from marathon.

Number of subjects whose pain score based on 0-10 Numerical Rating Scale rating reduced over 2 points from pre-application to post- application, whose post-application score was reported within 10 seconds.
Day 1 - immediately at the end of the race, assessed within the Recovery Application Zone Questionnaire.
Percentage of participants reporting a cooling sensation within 10 seconds/ immediately after application.
Tijdsspanne: Day 1 - immediately at the end of the race, assessed within the Recovery Application Zone Questionnaire.
Percentage of participants reporting a cooling sensation within 10 seconds or immediately after application. Participants reported if they experienced a cooling sensation (YES/ NO) and for the next question, reported if that occurred within 10 seconds / immediately after application or over 10 seconds.
Day 1 - immediately at the end of the race, assessed within the Recovery Application Zone Questionnaire.
Percentage of participants experiencing cooling sensation lasting 2 hours or more after topically applied menthol use
Tijdsspanne: Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.

Percentage of participants experiencing cooling sensation lasting 2 hours or more after topically applied menthol use, by product, participants who reported a cooling sensation (YES/ NO) and for the next question, participants reported duration of cooling assessed as follows:

1.Less than 10 minutes 2.10 minutes to less than 30 minutes 3.30 minutes to less than 60 minutes 4.60 minutes to less than 2 hours 5.2 hours to less than 3 hours 6.3 hours to less than 4 hours 7.4 hours or more
Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.
Rating of Intensity from the use of topically applied menthol when used after the marathon
Tijdsspanne: Day 1 - immediately at the end of the race, assessed within the Recovery Application Zone Questionnaire.

Average rating for intensity from the use of topically applied menthol when used after the marathon.

Intensity of cooling sensation is assessed post application of topically applied menthol, calculated using a 1-10 Rating Scale question to rate intensity of cooling sensation, where 1 is a mild cooling sensation, 10 is an extremely intense cooling sensation.
Day 1 - immediately at the end of the race, assessed within the Recovery Application Zone Questionnaire.
Rating of Intensity from the use of topically applied menthol when used during the marathon
Tijdsspanne: Retrospective recall data from the end of race questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.

Average rating for intensity from the use of topically applied menthol when used during the marathon.

Intensity of cooling sensation is assessed post application of topically applied menthol, calculated using a 1-10 Rating Scale question on intensity of cooling sensation: scale 1-10, where 1 is a mild cooling sensation, 10 is an extremely intense cooling sensation.
Retrospective recall data from the end of race questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.
Rating of Liking from the use of topically applied menthol when used after the marathon
Tijdsspanne: Day 1 - immediately at the end of the race, assessed within the Recovery Application Zone Questionnaire.

Average rating for overall liking from the use of topically applied menthol when used after the marathon.

Overall liking of cooling sensation is assessed post application of topically applied menthol, calculated using a 1-10 Rating Scale question to rate overall liking of cooling sensation, where 1 is dislike extremely and 10 is like extremely.
Day 1 - immediately at the end of the race, assessed within the Recovery Application Zone Questionnaire.
Rating of Liking from the use of topically applied menthol when used during the marathon
Tijdsspanne: Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.

Average rating for overall liking from the use of topically applied menthol when used during the marathon.

Overall liking of cooling sensation is assessed post application of topically applied menthol, calculated using a 1-10 Rating Scale question to rate overall liking of cooling sensation, where 1 is dislike extremely and 10 is like extremely.
Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.
Percentage agreement that the cooling sensation from topically applied menthol helped to reduce pain.
Tijdsspanne: Day 1 - immediately at the end of the race, assessed within the Recovery Application Zone Questionnaire.
Based on data collected in the Recovery Application Zone Questionnaire, the number of subjects who respond, "strongly agree" and "agree" to Likert Scale statement that the cooling sensation from topically applied menthol helped to reduce pain.
Day 1 - immediately at the end of the race, assessed within the Recovery Application Zone Questionnaire.
Proportion of participants agreement regarding statements about topically applied menthol
Tijdsspanne: Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.

Participants who respond, "strongly agree" or "agree" to Likert Scale statements in the End of Race Questionnaire:

  1. Biofreeze relieves pain;
  2. The cooling sensation from Biofreeze reduces pain;
  3. Biofreeze use during the race helped me run/ walk over the finish line by relieving my pain.
Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.
Percentage of participants experiencing pain relief lasting 2 hours or more after topically applied menthol
Tijdsspanne: Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.

Based on retrospective recall data from the End of Race Questionnaire, participants who responded to a single-select question:

2 hours to less than 3 hours, 3 hours to less than 4 hours, 4 hours or more
Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.
Analysis of Covariance (ANCOVA) model to assess association between age and pain outcomes (severity, location), and topically applied menthol use during the marathon
Tijdsspanne: Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.

To assess impact of the following aspects on pain experience (pain severity and location and topically applied menthol use) during the marathon (based on retrospective recall data from the End of Race Questionnaire):

Age (self reported: ranges in years: 18-25; 26-35; 36-45; 46-55; 56-65; 66-75; 76 or older)

Pain Severity: (self-rated pain before use & immediately after Biofreeze use, both via Numeric Rating Scales 0-10 where 0 is no pain and 10 is the worst pain imaginable)

Pain Location (self-reported pain regions, e.g. pelvis; groin; knee; none of these)

Biofreeze Use:

  • whether it was used (yes/no)
  • type of Biofreeze product used (roll-on; base gel; professional gel; aerosol spray; patch)
  • when it was used (during the race; after the race in the recovery zone; after the race)
Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.
Analysis of Covariance (ANCOVA) model to assess association between sex and pain outcomes (severity, location), and topically applied menthol use during the marathon
Tijdsspanne: Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.

To assess impact of the following aspects on pain experience (pain severity and location and topically applied menthol use) during the marathon (based on retrospective recall data from the End of Race Questionnaire):

Sex (self reported: male; female; non-binary; prefer not to say) Pain Severity: (self-rated pain before use & immediately after Biofreeze use, both via Numeric Rating Scales 0-10 where 0 is no pain and 10 is the worst pain imaginable)

Pain Location (self-reported pain regions, e.g. pelvis; groin; knee; none of these)

Biofreeze Use:

  • whether it was used (yes/no)
  • type of Biofreeze product used (roll-on; base gel; professional gel; aerosol spray; patch)
  • when it was used (during the race; after the race in the recovery zone; after the race)
Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.
Analysis of Covariance (ANCOVA) model to assess association between menstrual cycle stage, menopausal status and pain outcomes (severity, location), and topically applied menthol use during the marathon
Tijdsspanne: Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.

To assess impact of the following aspects on pain experience (pain severity and location and topically applied menthol use) during the marathon (based on retrospective recall data from the End of Race Questionnaire):

Menstrual cycle stage and menopausal status (self-reported status; for example Have menstrual cycle, was on my period; Post menopausal)

Pain Severity: (self-rated pain before use & immediately after Biofreeze use, both via Numeric Rating Scales 0-10 where 0 is no pain and 10 is the worst pain imaginable)

Pain Location (self-reported pain regions, e.g. pelvis; groin; knee; none of these)

Biofreeze Use:

  • whether it was used (yes/no)
  • type of Biofreeze product used (roll-on; base gel; professional gel; aerosol spray; patch)
  • when it was used (during the race; after the race in the recovery zone; after the race)
Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.
Analysis of Covariance (ANCOVA) model to assess association between amount of sleep, quality of sleep the night before the marathon and pain outcomes (severity, location), and topically applied menthol use during the marathon
Tijdsspanne: Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.

To assess impact of the following aspects on pain experience (pain severity and location and topically applied menthol use) during the marathon (based on retrospective recall data from the End of Race Questionnaire):

Amount and quality of sleep the night before the marathon: (self reported: hours slept example: less than 1 hour, 2 hours to less than 3, 3 hours to less than 4, more than 8 hours; Sleep quality: very good; fairly good; fairly bad; very bad)

Pain Severity: (self-rated pain before use & immediately after Biofreeze use, both via Numeric Rating Scales 0-10 where 0 is no pain and 10 is the worst pain imaginable)

Pain Location (self-reported pain regions, e.g. pelvis; groin; knee; none of these)

Biofreeze Use:

  • whether it was used (yes/no)
  • type of Biofreeze product used (roll-on; base gel; professional gel; aerosol spray; patch)
  • when it was used (during the race; after the race in the recovery zone; after the race)
Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.
Types of oral analgesic products used alongside topically applied menthol
Tijdsspanne: Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.
Participants reported types of oral analgesia used alongside topically applied menthol during the marathon and recovery period through the following question (option to select): Ibuprofen /Acetaminophen /Opioid /Naproxen /Aspirin / Combination Analgesic / Other.
Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.
Number of participants who used analgesic products alongside topically applied menthol for pain relief during marathon
Tijdsspanne: Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.

Types of oral analgesia used alongside topically applied menthol and number of participants who used each during the race and recovery period.

Participants reported use of oral analgesic products alongside topically applied menthol by single-select (YES/NO) question.
Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Reckitt Benckiser Healthcare (UK) Limited

Onderzoekers

  • Hoofdonderzoeker: Neeta Yousaf, PHD, Curion Strategic Product Insights

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

12 oktober 2025

Primaire voltooiing (Werkelijk)

12 oktober 2025

Studie voltooiing (Werkelijk)

12 oktober 2025

Studieregistratiedata

Eerst ingediend

5 maart 2026

Eerst ingediend dat voldeed aan de QC-criteria

27 april 2026

Eerst geplaatst (Werkelijk)

4 mei 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

4 mei 2026

Laatste update ingediend die voldeed aan QC-criteria

27 april 2026

Laatst geverifieerd

1 april 2026

Meer informatie

Termen gerelateerd aan deze studie

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • 5106901

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Beschrijving IPD-plan

IPD is completely anonymised and each participant can no longer be identified.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

product vervaardigd in en geëxporteerd uit de V.S.

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren